Haemodynamic and renal effects of tadalafil in patients with cirrhosis  

作　　者：Georgios N Kalambokis Paraskevi Kosta Konstantinos Pappas Epameinondas V Tsianos 

机构地区：[1]1st Division of Internal Medicine and Hepato-Gastroenterology Unit,University Hospital,Medical School of Ioannina [2]Department of Radiology,University Hospital [3]Department of Cardiology,University Hospital

出　　处：《World Journal of Gastroenterology》2010年第39期5009-5010,共2页世界胃肠病学杂志（英文版）

摘　　要：A recent report introduced the phosphodiesterase-5 inhibition by vardenafil as a novel treatment of portal hypertension in patients with cirrhosis.In the herein presented"letter to the editor",the administration of tadalafil did not influence portal haemodynamics but impaired systemic haemodynamics in patients with cirrhosis.Our observations concur with the results of a report in a previous issue of World Journal of Gastroenterology(October 2008).Moreover,tadalafil adversely affected renal function in patients with decompensated liver disease.A recent report introduced the phosphodiesterase-5 inhibition by vardenafil as a novel treatment of portal hypertension in patients with cirrhosis.In the herein presented'letter to the editor',the administration of tadalafil did not influence portal haemodynamics but impaired systemic haemodynamics in patients with cirrhosis.Our observations concur with the results of a report in a previous issue of World Journal of Gastroenterology(October 2008).Moreover,tadalafil adversely affected renal function in patients with decompensated liver disease.

关 键 词：TADALAFIL Portal hypertension CIRRHOSIS ASCITES Phosphodiesterase-5 inhibition 

分 类 号：R575.2[医药卫生—消化系统]